Mark J Amsbaugh1, Anita Mahajan2, Peter F Thall3, Mary Frances McAleer1, Arnold C Paulino1, David Grosshans1, Soumen Khatua4, Leena Ketonen5, Hiral Fontanilla6, Susan L McGovern7. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Princeton Radiation Oncology, Monroe, New Jersey. 7. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: slmcove@mdanderson.org.
Abstract
PURPOSE: To identify an optimal dose for reirradiation (reRT) of diffuse intrinsic pontine glioma. METHODS AND MATERIALS: ReRT dose levels were selected using an adaptive utility-based dose-finding method. The coprimary endpoints were toxicity (mild, moderate, high, or severe) and efficacy, evaluated 1 month after reRT. Efficacy was defined as improvements in imaging, clinical status, and quality of life. Secondary endpoints were progression-free and overall survival. Utility of each dose level was calculated based on a combined toxicity/efficacy score, ranging from 0 for (severe toxicity, no efficacy) to 100 for (mild toxicity, all 3 efficacy improvements). RESULTS: Twelve patients completed reRT at 3 dose levels: 24 Gy in 12 fractions (6 patients), 26.4 Gy in 12 fractions (4 patients), and 30.8 Gy in 14 fractions (2 patients). One patient treated at dose level 3 developed a grade 3 acute toxicity. Five of the 6 patients receiving 24 Gy demonstrated improvement in 2 of 3 efficacy domains, and the sixth demonstrated improvement in all efficacy domains. Of 4 patients receiving 26.4 Gy, 1 demonstrated no improvement, and 1 patient each demonstrated improvement in 1, 2, and 3 efficacy domains. Of 2 patients receiving 30.8 Gy, 1 demonstrated improvement in 3 efficacy domains, and 1 did not complete the quality of life and was not assessed. Mean utilities were 88 for dose level 1, 76 for dose level 2, and 25 for dose level 3. For all patients, the median overall survival was 19.5 months from initial diagnosis (95% confidence interval, 15.6-21.1 months), and the median progression-free survival was 4.5 months from the start of reRT (95% confidence interval, 2.7-6.2 months). CONCLUSIONS: ReRT can safely be delivered for progressive diffuse intrinsic pontine glioma. Clinical improvement was seen in almost all patients. Utility analysis suggests that a regimen of 24 Gy in 12 fractions is preferred.
PURPOSE: To identify an optimal dose for reirradiation (reRT) of diffuse intrinsic pontine glioma. METHODS AND MATERIALS: ReRT dose levels were selected using an adaptive utility-based dose-finding method. The coprimary endpoints were toxicity (mild, moderate, high, or severe) and efficacy, evaluated 1 month after reRT. Efficacy was defined as improvements in imaging, clinical status, and quality of life. Secondary endpoints were progression-free and overall survival. Utility of each dose level was calculated based on a combined toxicity/efficacy score, ranging from 0 for (severe toxicity, no efficacy) to 100 for (mild toxicity, all 3 efficacy improvements). RESULTS: Twelve patients completed reRT at 3 dose levels: 24 Gy in 12 fractions (6 patients), 26.4 Gy in 12 fractions (4 patients), and 30.8 Gy in 14 fractions (2 patients). One patient treated at dose level 3 developed a grade 3 acute toxicity. Five of the 6 patients receiving 24 Gy demonstrated improvement in 2 of 3 efficacy domains, and the sixth demonstrated improvement in all efficacy domains. Of 4 patients receiving 26.4 Gy, 1 demonstrated no improvement, and 1 patient each demonstrated improvement in 1, 2, and 3 efficacy domains. Of 2 patients receiving 30.8 Gy, 1 demonstrated improvement in 3 efficacy domains, and 1 did not complete the quality of life and was not assessed. Mean utilities were 88 for dose level 1, 76 for dose level 2, and 25 for dose level 3. For all patients, the median overall survival was 19.5 months from initial diagnosis (95% confidence interval, 15.6-21.1 months), and the median progression-free survival was 4.5 months from the start of reRT (95% confidence interval, 2.7-6.2 months). CONCLUSIONS: ReRT can safely be delivered for progressive diffuse intrinsic pontine glioma. Clinical improvement was seen in almost all patients. Utility analysis suggests that a regimen of 24 Gy in 12 fractions is preferred.
Authors: Lara Chavaz; Geert O Janssens; Stephanie Bolle; Henry Mandeville; Monica Ramos-Albiac; Karen Van Beek; Helen Benghiat; Bianca Hoeben; Andres Morales La Madrid; Clemens Seidel; Rolf-Dieter Kortmann; Darren Hargrave; Lorenza Gandola; Emilia Pecori; Dannis G van Vuurden; Veronica Biassoni; Maura Massimino; Christof M Kramm; Andre O von Bueren Journal: Front Oncol Date: 2022-06-22 Impact factor: 5.738
Authors: Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Hong In Yoon; Chan Woo Wee; Young Zoon Kim; Youngbeom Seo; Jung Ho Im; Yun Sik Dho; Kyung Hwan Kim; Je Beom Hong; Jae Sung Park; Seo Hee Choi; Min Sung Kim; Jangsup Moon; Kihwan Hwang; Ji Eun Park; Jin Mo Cho; Wan Soo Yoon; Se Hoon Kim; Young Il Kim; Ho Sung Kim; Kyoung Su Sung; Jin Ho Song; Min Ho Lee; Myung Hoon Han; Se Hoon Lee; Jong Hee Chang; Do Hoon Lim Journal: Brain Tumor Res Treat Date: 2021-04
Authors: Julianna K Bronk; Ping Hou; Mark J Amsbaugh; Soumen Khatua; Anita Mahajan; Leena Ketonen; Susan L McGovern Journal: Adv Radiat Oncol Date: 2021-11-14
Authors: Joshua D Bernstock; Samantha E Hoffman; Ari D Kappel; Pablo A Valdes; Walid Ibn Essayed; Neil V Klinger; Kyung-Don Kang; Stacie K Totsch; Hannah E Olsen; Charles W Schlappi; Katharina Filipski; Florian A Gessler; Lissa Baird; Mariella G Filbin; Rintaro Hashizume; Oren J Becher; Gregory K Friedman Journal: Oncoimmunology Date: 2022-09-26 Impact factor: 7.723
Authors: Fatma E El-Khouly; Sophie E M Veldhuijzen van Zanten; Dannis G van Vuurden; Gertjan J L Kaspers; Marc H A Jansen; Dewi P Bakker; Esther Sanchez Aliaga; N Harry Hendrikse; W Peter Vandertop Journal: J Neurooncol Date: 2021-05-07 Impact factor: 4.130